Investigation and intervening therapy to depression of malignant hematologic diseases
10.3760/cma.j.issn.1009-9921.2009.07.019
- VernacularTitle:血液肿瘤患者抑郁障碍的调查及干预性治疗
- Author:
Xiaoying HUA
;
Xiaugshan CAO
;
Xinyu QIAN
;
Weiying GU
;
Jian SUN
;
Bei ZHAO
;
Ming ZHOU
- Publication Type:Journal Article
- Keywords:
Depression;
Intervention studies;
Hematologic neoplasms
- From:
Journal of Leukemia & Lymphoma
2009;18(7):432-434
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the mental status of malignant hematologic patients, explore the morbidity of depression in malignant hematologic patients, and investigate valid interventional treatment on them. Methods 134 malignant hematologic patients were evaluated by SDS and HAMD, and 49 patientswere selected who was diagnosed depressive disorder then randomly divided into 2 groups. One was experimental group and the other control group. The patients of experimental group were treated with antidepressant drug and mental intervention during common therapy, while the patients of control group only took common therapy. The change of immunological function after treatment was detected. Results The morbidity of depression in malignant hematologic patients was 37 %. The scores of SDS and HAMD were significandy decreased and the depressive symptoms were notablely improved in experimental group and there were significant differences after treatment and before treatment (P <0.01), but there was no significant difference in control group (P >0.1). The NPY plasma levels significantly increased after treatment in experimental group(P <0.01), but there was no significant difference in control group(P >0.05); the CD+4/CD+4 values of patients in the experimental group were significantly increased after treatments. Statistical analysis revealed significant differences in the experimental group patients between pre-treat and after-treat (P <0,05),but no obvious difference in the patients of control group (P>0.5). Conclusion Mental intervention and antidepressive treatment can improve all of the depression, immunological function and quality of life of malignant hematologic patients.
